Behind the Rebound in French VC Fundraising: Structural Differentiation and the Stabilizing Role of State Capital

Opening: Is the Rebound in French VC Fundraising Structural or Accidental?

In the first half of 2026, French venture capital fundraising reached €2.4 billion, already surpassing the full-year 2025 total of €1.7 billion. Behind the good news, the market is heavily dependent on one mega-deal: the biopharma fund Jeito Capital II closed with $1.2 billion (approximately €1.07 billion), accounting for over 40% of the total fundraising. Excluding this deal, H1 fundraising would be only around €1.3 billion, showing limited growth compared to the same period in 2025.

What does this rebound in the French VC market reveal about the structural changes taking place in France's innovation economy?

Background: Hot Money Returns, but Flows Are Highly Concentrated

According to PitchBook's Q2 2026 France market snapshot, aside from Jeito, Kurma Biofund IV also closed with €215 million, backed by LPs including Eurazeo, Australian pharmaceutical company CSL, the European Investment Fund (EIF), and Bpifrance. Overall, large biopharma funds are leading the fundraising charge.

But excluding these top-tier funds, the stability of the remaining market relies heavily on sustained state capital investment. Bpifrance remains the most important player in the French VC ecosystem, accounting for about 30% of seed and early-stage investments. In February 2025, it also committed €10 billion to the AI sector. Additionally, the Tibi 2 initiative (launched in 2023) has secured commitments from over 30 French institutional investors, corporations, and family offices, aiming to deploy a total of around €7 billion into qualifying tech funds by the end of 2026.

Meanwhile, funds currently in the market include the late-stage fund Atlantic Vantage Point targeting €1.5 billion (currently the largest in France) and Bpifrance's Large Venture Fund 3 (targeting €750 million).

Deeper Logic: Why Is French VC Fundraising So Concentrated?

The shift in France's VC fundraising structure can be understood from three perspectives:

1. Capital flows toward high-certainty sectors: Biopharma and AI are currently the most favored areas for global VCs. France boasts globally competitive funds like Jeito and Kurma in these fields, along with numerous research-to-commercialization projects. When market uncertainty is high, LPs prefer to invest in industries with clear technological moats and long-term return potential.

2. State capital acts as a "ballast": Bpifrance and the Tibi 2 initiative provide a stable source of funding for the market. Compared to other major European economies, France's direct involvement in VC through government-guided funds and sovereign funds reduces the impact of market volatility on early-stage companies. This "state capitalism" model is unique on the continent.3. Cautious Private Capital, Policy Funds Step In: Although the interest rate environment has improved, European institutional investors remain conservative in their allocation to risk assets. France has used policy funds to fill the gap left by private capital, maintaining the total fundraising scale, but this has also deepened the market's reliance on state capital.

Impact on the French Economy: Enhanced Resilience of the Innovation Ecosystem but Emerging Structural Imbalance Risks

For French Enterprises - Early-stage enterprises benefit from stable state capital supply: Bpifrance's continuous investment means French startups have easier access to funding during seed and Series A rounds, helping to reduce the 'valley of death' risk. - Late-stage enterprises face challenges: Except for a few top-tier funds, large-scale fundraising in later stages remains difficult. The fundraising progress of funds like Atlantic Vantage Point will determine whether France has enough 'growth capital' to retain its unicorns.

For Industries - Biomedicine and AI have become France's two key innovation sectors, but if capital becomes overly concentrated in these areas, it may crowd out innovation resources from other industries (such as clean tech, advanced manufacturing). - The strong presence of state capital may suppress the competitive vitality of market-oriented VCs, and in the long term, one must be wary of the 'anchoring effect'.

For Consumers - In the short term, improvements in employment and products from technological innovation are not significant, but breakthroughs in AI and biomedicine are expected to translate into economic growth points and improved public services in the next 5-10 years.

European and Global Impact: Can the French Model Become a Template for European VC?

France's model of maintaining VC fundraising momentum through a 'government + market' combination contrasts sharply with Germany (relying on corporate venture capital) and the UK (market-oriented). Against the backdrop of a general slowdown in European VC fundraising, France has performed relatively robustly, thanks to forward-looking policies.

• France's centralizing tendency in VC may make it a capital hub for European biomedicine and AI, but coordination with other countries is needed to avoid fragmentation.
• If plans like Tibi 2 are executed smoothly, France is expected to attract over €10 billion in institutional funds into tech funds cumulatively by the end of 2026, which will significantly enhance Paris's status as a European fintech hub.

Long-term Trend Judgment: In the Next 3-10 Years, France's Innovation Economy Will Undergo Three Evolutions

1. Capital structure gradually shifts from 'state-led' to 'public-private partnership': As inflation falls and interest rates normalize, private capital will re-enter, but state capital will retain a certain proportion, forming a unique 'French model'.

2. Industry concentration may rise first and then fall: In the short term, capital will continue to gather in biomedicine and AI, but policy funds may use 'mandatory diversification' clauses to direct capital toward national strategic areas such as deep tech and climate tech.3. Exit mechanisms will determine ultimate success or failure: The long-term sustainability of the rebound in French VC fundraising depends on the activity of the IPO market and the M&A market. If progress is made in European capital market reforms (such as the simplification of EU listing rules), more French tech companies will be able to go public, creating a virtuous cycle.

Conclusion

The real significance of the rebound in French VC fundraising lies not in the scale of growth, but in confirming a structural characteristic that is taking shape: state capital and policy-driven programs are becoming the core defense line for France's innovation economy against global capital cycle fluctuations. This defense line ensures France's international competitiveness in biopharmaceuticals and AI, but also raises long-term questions about the efficiency of capital allocation. Whether France can maintain market vitality while retaining strategic autonomy will be a key variable in observing the European innovation landscape over the next decade.